Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

• Main Authors: Yunda Huang (Author), Lily Zhang (Author), Amanda Eaton (Author), Nonhlanhla N. Mkhize (Author), Lindsay N. Carpp (Author), Erika Rudnicki (Author), Allan DeCamp (Author), Michal Juraska (Author), April Randhawa (Author), Adrian McDermott (Author), Julie Ledgerwood (Author), Philip Andrew (Author), Shelly Karuna (Author), Srilatha Edupuganti (Author), Nyaradzo Mgodi (Author), Myron Cohen (Author), Lawrence Corey (Author), John Mascola (Author), Peter B. Gilbert (Author), Lynn Morris (Author), David C. Montefiori (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

VRC01 is being evaluated in the AMP efficacy trials, the first assessment of a passively administered broadly neutralizing monoclonal antibody (bnAb) for HIV-1 prevention. A key analysis will assess serum VRC01-mediated neutralization as a potential correlate of protection. To prepare for this analy...